Poland· PL-100513673

Welireg

A belzutifan product containing belzutifanum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC L01XX74

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedWeliregATCL01XX74REGISTER NO.PL-100513673PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Belzutifan is registered in 14 of 19 countries.

Countries holding a registration under ATC L01XX74 (belzutifan), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Belzutifan · ATC L01XX74

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of belzutifan costs, country by country.

Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Belzutifan · price per daily dose (0.12 g)

USD · FX 28 Sept 2026

  • FR France$0.54
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Belzutifanum
Manufacturer
Merck Sharp & Dohme B.V.
Country
Poland (PL)
ATC code
L01XX74
ATC class
Belzutifan
Defined daily dose
0.12 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    00191778024418

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Belzutifan in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All belzutifan products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Welireg
  • Liechtenstein · Welireg
  • Norway · Welireg

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ce9c9e74-6f23-4bc2-85f3-96861acadeba
GET /v1/drugs/ce9c9e74-6f23-4bc2-85f3-96861acadeba?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "40 mg",
  "packaging": "Rpz ¦ EU/1/24/1893/001 ¦ 160553\n30 tabl.\n00191778024418 ¦ Rpz ¦ EU/1/24/1893/002 ¦ 160554\n90 tabl. opakowanie zbiorcze",
  "substance": "Belzutifanum 40 mg",
  "common_name": "Belzutifanum",
  "pl_product_id": "100513673",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about belzutifan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.